- Updated Therapeutic Implications - Promotion of tumor type-specific level of evidence for an alteration

| Gene | Mutation            | Cancer Type                     | Level-associated Drug(s) in OncoKB™                                                                                                                                 | Previous Level | Updated Level | Evidence                                                                                                                                                                                                                                                                                                                                                                                                          |
| :--- | :------------------ | :------------------------------ | :------------------------------------------------------------------------------------------------------------------------------------------------------------------ | :------------- | :------------ | :---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| KRAS | Oncogenic Mutations | Low-Grade Serous Ovarian Cancer | _Drug(s) added to OncoKB™:_<br/> Avutometinib \+ Defactinib (Level 1\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Binimetinib, Cobimetinib, Trametinib (Level 4\) | 4              | 1             | [FDA approval of avutometinib plus defactinib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low); Abstract: [Grisham et al. Abstract \#814605, 2025 SGO Annual Meeting on Women’s Cancer](https://www.verastem.com/wp-content/uploads/2025/03/RAMP-201-Oral-Presentation-SGO-2025_03.17.25f.pdf) |

####

- Addition of 4 new genes:
  - CTC1
  - GSTP1
  - TPMT
  - TYMS
